Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

CAPSID
  NCT04433910		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
53/52 inconclusive
  • inconclusive 58 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
CP-COVID-19
  NCT04332835		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
49/51 inconclusive
  • inconclusive 12 % increase in viral clearance (PE) with a moderate degree of certainty due to some concern in risk of bias
O’Donnell
  NCT04359810		 RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
150/73 inconclusive
  • inconclusive 38 % increase in clinical improvement (28-day) (PE) with a high degree of certainty due to low risk of bias
Pouladzadeh
  IRCT20200310046736N1		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
31/31 suggested
  • suggested 6.3-fold increase in clinical improvement,clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
Raman
  CTRI/2020/06/026222		 RCTimmunoglobulin therapy standard of careCOVID-19 severe or criticallysome concern
50/50 suggested
  • suggested 35.4-fold increase in viral clearance ,viral clearance by day 14 with a moderate degree of certainty due to some concern in risk of bias
RECOVER
  EudCT 2020-001632-10		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallylow
43/47 inconclusive
    REMAP-CAP (plasma)
          NCT02735707    		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallylow
    		1095/916 safety concern
    • statistically significant 1.3-fold increase in serious adverse events with a high degree of certainty due to low risk of bias
    Sekine (PLACOVID)
          NCT04547660    		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
    		80/80 inconclusive
    • inconclusive 6 % decrease in clinical improvement,clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    AlQahtani
          NCT04356534    		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
    		20/20 inconclusive
    • inconclusive 33 % decrease in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
    Li
          ChiCTR2000029757    		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
    		52/51 inconclusive
    • inconclusive 40 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    PlasmAr
          NCT04344535    		 RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
    		228/106 inconclusive
    • inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
    Rasheed RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
    		21/28 inconclusive
      Tabarsi
              IRCT20151227025726N2      		 RCTimmunoglobulin therapy standard of careCOVID-19 severe or criticallysome concern
      		52/32 inconclusive
      • inconclusive 10 % increase in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
      • inconclusive 49 % increase in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
      • inconclusive 44 % decrease in ICU admission (PE) with a moderate degree of certainty due to some concern in risk of bias
      8 studies excluded by filtering options (3 RCT / 5 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons